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Background: Trastuzumab (Herceptin® [H]) is the standard of care for HER2-positive locally advanced/metastatic
breast cancer and gastric/gastroesophageal junction (GEJ) cancer. However, there is a paucity of data available on
long-term H treatment of patients. The Rollover Protocol (ROP) Study was conducted to report safety data for
patients with HER2-positive locally advanced/metastatic breast and gastric/GEJ cancer who have received long-term
H therapy (≥ 5 years and ≥ 3 years for breast and gastric/GEJ cancer, respectively).
Methods: The ROP Study was a single-arm, multicenter, international continuation trial of H in patients who had
previously completed a global Roche-sponsored trial with H therapy, had stable disease, and were receiving H at
the end of the lead-in trial. Patients with chronic heart failure during the lead-in trial could be included following a
risk–benefit analysis. The primary objectives were to provide H therapy to patients with HER2-overexpressing locally
advanced/metastatic breast or gastric/GEJ cancer at the end of the lead-in study, and to follow the long-term
outcomes and long-term overall safety in these patients.
Results: Twenty-five of 69 patients enrolled in the ROP Study received long-term H therapy (19 breast cancer and 6
gastric/GEJ cancer). The median duration of H treatment for patients with breast cancer was 8 years 7 months, and
5 years 2 months for patients with gastric/GEJ cancer. The cardiac status of the patients remained stable over time,
with no serious cardiac adverse events or marked changes in left ventricular ejection fraction (LVEF). The median
overall worst LVEF measurement was 57.0%, and no patients experienced an LVEF of < 45% (range 47–63%). There
were no serious adverse events related to study treatment.
Conclusions: These results suggest that H has an acceptable safety profile and was well tolerated in patients who
received long-term H therapy (≥ 5 years and ≥ 3 years for breast and gastric/GEJ cancer, respectively). Further
investigation and reporting of long-term H therapy would be valuable.
Trial registration: This study was retrospectively registered on March 24, 2016 with Clinicaltrials.gov, number
NCT02721641.
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Trastuzumab (Herceptin® [H]; F. Hoffmann-La Roche
Ltd, Basel, Switzerland) was first approved in 1998 in
the United States, and first approved in 2000 in Europe,
for the treatment of HER2-positive metastatic breast
cancer; H has since been approved in more than 125
countries worldwide, which has led to establishing a new
standard of care treatment for HER2-positive disease
[1–5]. Despite the number of patients treated with H
worldwide, there is a paucity of data reported on long-
term H treatment. This Rollover Protocol (ROP) Study
was initiated in 1998 to allow patients with HER2-
positive metastatic breast cancer outside of the US, who
had previously participated in Roche-sponsored HER2-
positive breast cancer studies, to continue H therapy
until disease progression.
H was approved in 2010 in both Europe and in the US
for the treatment of HER2-positive locally advanced or
metastatic gastric or gastroesophageal junction (GEJ)
adenocarcinoma, and the ROP Study was expanded to
provide H therapy until disease progression to patients
who had completed any Roche-sponsored HER2-positive
gastric/GEJ cancer studies.
The ROP Study was conducted to report safety data
for patients with HER2-positive locally advanced/
metastatic breast cancer and HER2-positive locally
advanced gastric/GEJ cancer who have received
long-term H therapy, defined as ≥ 5 years of H ther-
apy for patients with HER2-positive locally advanced/
metastatic breast cancer and ≥ 3 years of H therapy
for patients with HER2-positive locally advanced
gastric/GEJ cancer.Methods
Study design
The ROP Study was a single-arm, multicenter,
international continuation trial of H in participants who
had previously completed a global Roche-sponsored trial
with H therapy. The ROP Study was performed in accord-
ance with the guidelines for Good Clinical Practice and
the Declaration of Helsinki. Approval for the study proto-
col and any accompanying information provided to pa-
tients was obtained from ethics committees at each site
(see Additional file 1). The ROP Study is registered on
Clinicaltrials.gov, number NCT02721641.Study objectives
The ROP Study’s primary objectives were to provide H
therapy to patients with HER2-overexpressing locally ad-
vanced/metastatic breast or gastric/GEJ cancer who had
completed any global Roche-sponsored H clinical study,
and to follow the long-term outcomes and long-term
overall safety in patients treated with H.Patients
Patients were eligible to participate in the ROP Study if
they had stable disease, and had their termination data,
including tumor assessment and laboratory data, re-
corded on the Case Report Form (CRF) while receiving
H at the end of their H lead-in trial [1, 2, 6–12]. Patients
had received long-term H therapy, defined as ≥ 5 years for
patients with HER2-positive locally advanced/metastatic
breast cancer and ≥ 3 years for patients with HER2-
positive locally advanced gastric/GEJ cancer. Patients
with signs of chronic heart failure during the lead-in
trial could be included following a risk–benefit assess-
ment by the investigator. Key exclusion criteria were
pregnant or nursing women, women of childbearing
potential unless using effective contraception, severe
dyspnea requiring supplementary oxygen therapy, and
severe uncontrolled systemic disease. Signed, informed
consent was obtained from all patients.
Study treatment
Patients previously treated with H therapy continued to
receive intravenous H (H IV) therapy administered ac-
cording to the standard H IV weekly (4 mg/kg loading
dose followed by weekly 2 mg/kg maintenance doses
starting a week after the loading dose) or 3-weekly
(8 mg/kg loading dose followed by 3-weekly 6 mg/kg
maintenance doses starting 3 weeks after the loading
dose) schedule, at the discretion of the treating phys-
ician. H therapy was continued until disease progression,
investigator-assessed lack of treatment benefit, unaccept-
able toxicity, patient decision, or patient death. H
administration could be delayed in the event of cardiac
toxicity following an algorithm based on left ventricular
ejection fraction (LVEF) assessment, but no dose modifi-
cations were permitted. If delayed, H was reinitiated in
accordance with the reloading guidelines. For patients
whose dose was delayed by ≤ 7 days, a maintenance dose
was administered as soon as possible and subsequent
maintenance doses were continued according to the ori-
ginal schedule. For those whose dose was delayed by >
7 days, a loading dose of 8 mg/kg or 4 mg/kg (depending
on the patient’s dosing schedule) was administered and
then maintenance doses were reinitiated and adminis-
tered at regular intervals from that point. In addition to
H therapy, continuation of treatment with other antican-
cer drugs at the same dose and schedule as that received
in the H lead-in trial was permitted, provided that the
treatment was still ongoing at completion of the lead-in
trial and that it was still considered beneficial for the
patient.
Assessments
Tumor assessments for disease progression were per-
formed as clinically indicated and at the discretion of




Median age (range) 55.0 (38–75)
Indication, n (%)
Breast cancer 19 (76.0)





Müller et al. BMC Cancer  (2018) 18:295 Page 3 of 6the investigator, and the date of disease progression was
recorded in the CRF. Cardiac status was assessed using
an echocardiogram or multigated acquisition scan as
clinically indicated. Cardiac failure (New York Heart
Association [NYHA] class II–IV) was reported as a
serious adverse event (SAE), and was graded as per
NCI-CTCAE version 3 criteria or NCI-CTC version 2
and the NYHA classification system. SAEs were reported
per the ICH Guideline for Clinical Safety Data
Management, Definitions and Standards for Expedited
Reporting, Topic E2. Hematology and biochemistry la-
boratory assessments were performed as per the stand-
ard medical practice at each site. The date of, and






Panama 1 (4.0)Statistical analyses
The current analysis is descriptive and safety data are
summarized herein. Sample size calculation was not ap-
plicable due to the nature of the study, and all eligible
patients were included. No formal hypothesis testing
was performed.Poland 2 (8.0)
Portugal 1 (4.0)
Republic of Korea 6 (24.0)
Russia 4 (16.0)
Abbreviation: H trastuzumab (Herceptin®)Results
Patients
Sixty-nine patients were enrolled in the ROP Study at 38
medical centers in 17 countries. Of these, 25 patients en-
rolled in 17 medical centers in 11 countries had received
long-term H therapy, defined as ≥ 5 years of H therapy
for patients with HER2-positive locally advanced or
metastatic breast cancer and ≥ 3 years of H therapy for
patients with HER2-positive locally advanced or meta-
static gastric/GEJ cancer. These patients were included
in the ROP Study after completing one of the nine glo-
bal Roche-sponsored H trials in Table 1. Their baseline
patient demographics and clinical characteristics are
shown in Table 2. The median age at baseline of all
patients included in the current analysis was 55 years
(range 38–75 years) and 80% of patients were femaleTable 1 Summary of Roche-sponsored lead-in H trials for the ROP S
Lead-in protocol ID number Study design Patient population
BO16216 Anastrozole ± H Breast cancer
BO18255 H + cisplatin + FU or X Gastric cancer
H0648g H + AC or pac Breast cancer
H0649g H monotherapy Breast cancer
M77001 H + T Breast cancer
M77003 H + EC Breast cancer
MO16419 H + T + X Breast cancer
WO16229 H monotherapy Breast cancer
WO17229 H + T or pac Breast cancer
Abbreviations: A anthracycline, C cyclophosphamide, E epirubicin, H trastuzumab (H
X capecitabine(Table 2). The 19 patients with HER2-positive locally
advanced/metastatic breast cancer were female and
had a median age of 53 years (range 38–75 years).
The remaining six patients (five males and one fe-
male) had HER2-positive locally advanced/metastatic
gastric/GEJ cancer and had a median age of 61 years
(range 52–74 years).
At the end of the ROP Study, all patients included in
this analysis had withdrawn from study treatment.
Reasons for withdrawal included the occurrence of AEs
(n = 1; 4%); insufficient therapeutic response, includingtudy










erceptin®), FU fluorouracil, pac paclitaxel, ROP Rollover Protocol, T docetaxel,
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available H therapy (n = 2; 8%); and refusal of treatment
(n = 1; 4%). Other reasons for withdrawal were reported
for 15 patients (60%), and included: study completion/
closure (n = 5); sponsor request (n = 4); investigator
decision (n = 3); switch to subcutaneous trastuzumab
(Herceptin® SC, F. Hoffmann-La Roche Ltd) (n = 2); and
agreement with the patient to discontinue treatment
until further disease progression (n = 1) (Table 3).
Treatment duration
The median duration of H treatment in patients with
breast cancer was 8 years and 7 months (3124 days), with
a range of 5 years and 4 months to 13 years and 11 months
(1940–5068 days). For patients with gastric/GEJ cancer,
the median duration of H treatment was 5 years and
2 months (1886 days) with a range of 3 years and 4 months
to 7 years and 4 months (1214–2677 days).Safety
Figure 1 shows the worst LVEF for each year of treat-
ment. LVEF measurements were available for 20 of the
25 patients included in these analyses. The cardiac status
of these patients remained stable over time, with no
marked changes in LVEF. The median overall worst
LVEF measurement was 57.0% and no patients experi-
enced an LVEF of < 45% (range 47–63%).
In total, seven of the 25 patients (28.0%) reported
SAEs (Table 4), none of which was related to study treat-
ment. Reported SAEs were pain, septic arthritis, erysip-
elas, lung cancer, fibula fracture, urinary tract infection
and a broken leg, which all occurred in one patient
(4.0%) each (Table 4). There were no reports of any car-
diac SAEs or SAEs that led to study withdrawal, and no
patients died while on study treatment.Table 3 Reasons for study withdrawal
Reason for study withdrawal, n (%) H
N = 25
AE/intercurrent illness 1 (4.0)
Insufficient therapeutic responsea 6 (24.0)
Switch to commercially available H treatment 2 (8.0)
Refusal of treatment 1 (4.0)
Other 15 (60.0)
Study completion/closure 5 (20.0)
Sponsor request 4 (16.0)
Investigator decision 3 (12.0)
Switch to H SC 2 (8.0)
Treatment discontinued until further disease progression 1 (4.0)
aIncludes patients who experienced disease progression
Abbreviations: AE adverse event, H trastuzumab (Herceptin®), H SC
subcutaneous trastuzumab (Herceptin® SC)Discussion
An established body of clinical evidence has led to
worldwide approvals of H as the standard of care for the
treatment of patients with HER2-positive locally ad-
vanced/metastatic breast cancer and patients with
HER2-positive locally advanced/metastatic gastric/GEJ
cancer [4, 5]. Tolerability of H therapy in these patients
has also been well established. As of September 2016,
over 2.3 million patients have been treated with H ther-
apy worldwide (data on file). However, despite this abun-
dance of clinical experience, there is a paucity of data
reported on long-term H treatment. Therefore, the re-
sults from this ROP Study of patients with long-term H
therapy are of significant interest to the medical oncol-
ogy community, as many physicians have ongoing quer-
ies about long-term management of patients with HER2-
positive locally advanced/metastatic breast cancer or
HER2-positive locally advanced/metastatic gastric/GEJ
cancer who are being treated with H. To our knowledge,
this is the longest study of patients receiving long-term
H therapy for HER2-positive breast cancer or for
HER2-positive gastric/GEJ cancer.
The results from this ROP Study suggest that long-
term H therapy in accordance with clinical practice had
an acceptable safety profile and was well tolerated. LVEF
was stable in these patients, and only seven SAEs were
reported in total, none of which was cardiac-related or
resulted in withdrawal from the study.
The risk of cardiac AEs is a concern of H treatment.
Earlier studies showed an increased incidence of cardiac
dysfunction in patients treated with H, predominantly
when H treatment was administered concurrently with
chemotherapy drugs, and particularly in combination
with anthracycline chemotherapy, in patients with
HER2-positive metastatic breast cancer [2, 13]. In this
ROP Study, however, the stable LVEF outcomes and the
absence of cardiac SAEs suggest that long-term H ther-
apy is feasible and without any additional cardiac safety
risk, particularly with continued patient care and moni-
toring according to standard practice. Four patients had
cardiac adverse events (three patients had tachycardia
and one patient palpitation) reported from their respect-
ive lead-in study; however, three cases were resolved
(one case resolution unknown) before the start of the
ROP Study, and only one patient was enrolled from a
lead-in study where patients had received H with anthra-
cyclines. Therefore, the low level of cardiac SAEs ob-
served in the ROP Study is due to enrollment of patients
who have each demonstrated cardiac tolerability to H
therapy in their prior lead-in studies, respectively. Other
publications studying long-term H treatment in meta-
static, locally advanced, or relapsed HER2-positive breast
cancer also reported low risk of cardiac AEs and contin-
ued response [3, 14–16]; nevertheless, there remains a
Fig. 1 Worst left ventricular ejection fraction (LVEF) for each year of treatment. N is the number of patients with an LVEF assessment on study
within the year on H. In cases of multiple LVEF assessments per patient within the same year, the lowest value is reported. Abbreviations: H
trastuzumab (Herceptin®), LVEF left ventricular ejection fraction
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term H treatment, as reported by the ROP Study.
A limitation of these analyses is that enrolled patients
had already been receiving H treatment previously, and
hence may have had a lowered baseline risk of cardiac
events and other SAEs in the ROP Study. In addition,
patients selected for this analysis had to have received
≥ 5 years of H therapy for HER2-positive locally ad-
vanced/metastatic breast cancer or ≥ 3 years of H
therapy for HER2-positive locally advanced/metastatic
gastric/GEJ cancer. This selection means that the
ROP Study population may not be representative of all pa-
tients with breast cancer or gastric/GEJ cancer who are
treated with H. Therefore, the safety risks reported here
may be underestimated in comparison with the general
population, who may have to stop H treatment early due
to AEs or disease progression. Underestimation of the
safety risks may also be a result of underreporting of SAEsTable 4 Summary of serious adverse events (SAEs)
Preferred term, n (%) H
N = 25
All SAEs 7 (28.0)
Pain 1 (4.0)
Septic arthritis 1 (4.0)
Erysipelas 1 (4.0)
Lung cancer 1 (4.0)
Fibula fracture 1 (4.0)
Urinary tract infection 1 (4.0)
Broken leg 1 (4.0)
Abbreviation: H trastuzumab (Herceptin®)or missing LVEF measurements, although it is unlikely
that relevant, serious cardiac AEs or significant LVEF de-
creases were missed in patients with long-term H therapy
in the ROP Study, given that the patients were monitored
regularly. Other limitations include differences in the
lead-in protocols, in study center practices, and in rollover
treatment regimens, and small patient numbers, which
may limit comparison between patients. Finally, there is a
paucity of additional information, such as tissue and
serum biomarkers, on patients who performed well on H
therapy and were enrolled into the ROP Study that may
predict long-term benefits of H therapy.Conclusions
In conclusion, the results of the ROP Study suggest that
in patients who received long-term H therapy for HER2-
positive disease (≥ 5 years and ≥ 3 years for patients with
HER2-positive locally advanced/metastatic breast and
gastric/GEJ cancer, respectively), treatment with H had
an acceptable safety profile and was well tolerated; fur-
ther investigation and reporting of long-term H therapy
would be valuable.Additional file
Additional file 1: Table S1. Institutions providing ethics approval for
the ROP Study. (PDF 40 kb)Abbreviations
AE: Adverse event; CRF: Case report form; GEJ: Gastroesophageal junction;
H: Trastuzumab; HER2: Human epidermal growth factor receptor 2;
IV: Intravenous; LVEF: Left ventricular ejection fraction; ROP: Rollover protocol;
SAE: Serious adverse event; SC: Subcutaneous
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